Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
about
Therapeutic cancer vaccines: past, present, and futureEndpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesp53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesA combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3.Therapeutic cancer vaccines: current status and moving forward.Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.Consumption of soy isoflavone enriched bread in men with prostate cancer is associated with reduced proinflammatory cytokines and immunosuppressive cells.From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancerDemystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.Immunotherapy for prostate cancer: biology and therapeutic approachesImmunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Immunotherapy and immune evasion in prostate cancer.Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer.The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.Effects of conventional therapeutic interventions on the number and function of regulatory T cells.Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges.Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review.Integrating Immunotherapies in Prostate Cancer.Immune Therapy for Prostate Cancer.New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials.Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.The immune system in cancer metastasis: friend or foe?Immunologic monitoring of cellular immune responses in cancer vaccine therapy.The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
P2860
Q26863283-AF7C7049-C4CD-4D66-B0FD-B1EF6254C89EQ27008070-BB8E239A-2B30-44AF-BC0B-D76C79F7231CQ34135426-5AF5285A-5D6F-4CB1-B6E0-0AE977B2EFC1Q34403480-621C34DF-FFE9-457D-A62F-8EAFFB2AF03DQ35195777-815B3559-37CD-43AF-9AFC-68A7A941F94AQ35894347-4E840589-1A6A-4333-81AB-22F5C1733C32Q36228550-8CB75722-2786-491D-BE20-DF90179E8ABAQ36249153-1B5985F4-FAD8-4C29-B2C6-B1A4C12EF326Q36293995-0E6FAA2E-9D13-401D-92F8-EE6108422279Q36567448-F24CDBF1-1287-40F6-A1D8-7045427C3CB9Q36884975-DCEE570C-07A4-40CD-8381-8637948256C6Q36910465-A5E8D023-9B46-4D8B-9052-F344042D5389Q37017085-FEA07FFC-FE64-4EA3-ADD7-78771ECA214BQ37017101-F242653A-4B4E-4091-B4AD-25627045C0EEQ37061769-0E4616A6-4874-4144-A3FC-26EA2B22B4E7Q37085326-0C91404D-DFB2-425A-A96D-904F289D4249Q37222061-C6498370-CFB6-41CB-BDA8-F3FE8B503FDEQ37390970-A84DA54E-DE85-4627-92BE-9CFB333EBE55Q37621444-FF6D9926-A1A7-48C3-962E-0DCBA69C59BFQ37732958-86555522-E6D7-428D-8A1D-7B8F4A1BA222Q38105081-B22DB5CE-D771-4A4E-A85D-A410C4E36775Q38184622-B261532C-99E1-4FDA-8B83-09E2C19B9981Q38413737-35CEED0D-286A-4EAE-A3EE-76DCB143CAB2Q38555581-5A40C90A-03C4-4D0F-99D3-48F7CE89FAA2Q38567067-F644D7A0-0CF7-47DE-B721-0E15A88BFB1EQ38982667-4A454623-0E45-4DB5-B650-59EF0E219056Q39093698-28B96D20-03EF-451C-805C-5BDD42CC5C10Q42174675-D1555E01-1834-45BB-9429-40CC706B111DQ42656251-C23CD4EB-B77B-41B1-9466-AFF0C6CDA42BQ42756613-48AC6615-68E3-4433-898C-F3D472571A83Q47876974-2D2B944A-46E0-482E-B4CB-750CDC66C45BQ53082188-A2C50659-C1D1-4279-B021-6744452CDDB5
P2860
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Analysis of circulating regula ...... r pre- versus post-vaccination
@ast
Analysis of circulating regula ...... r pre- versus post-vaccination
@en
type
label
Analysis of circulating regula ...... r pre- versus post-vaccination
@ast
Analysis of circulating regula ...... r pre- versus post-vaccination
@en
prefLabel
Analysis of circulating regula ...... r pre- versus post-vaccination
@ast
Analysis of circulating regula ...... r pre- versus post-vaccination
@en
P2093
P2860
P1476
Analysis of circulating regula ...... r pre- versus post-vaccination
@en
P2093
Connie J Rogers
James L Gulley
Jeffrey Schlom
Kenneth W Hance
Kwong Y Tsang
Matteo Vergati
Ngar-Yee Huen
Philip M Arlen
Ravi A Madan
Vittore Cereda
P2860
P2888
P304
P356
10.1007/S00262-010-0927-9
P577
2010-10-26T00:00:00Z